Texas Vioxx verdict overturned

Share this article:
Vioxx trial described as marketing stunt
Vioxx trial described as marketing stunt

A Texas appeals court has overturned a multimillion-dollar verdict involving Merck's withdrawn painkiller Vioxx the Wall Street Journal reports.

The verdict was overturned on grounds that there was insufficient evidence to link use of the drug to a fatal heart attack suffered by the spouse of plaintiff Felicia Garza of Rio Grande City, TX.

"The appellate court recognized that there was insufficient evidence supporting the jury's verdict and, accordingly, rendered a final judgment in the case in favor of Merck," said Ted Mayer, outside counsel for Merck, in a statement.

Garza sued Merck claiming that her husband's 2001 heart attack was caused by Vioxx. In April 2006, a jury found Merck liable and awarded $32 million in compensatory and punitive damages. Texas law caps such awards and the amount was later reduced to $7.75 million.

Vioxx was voluntarily pulled from the market in 2004 after studies found a link between the drug and an increased risk of heart attacks and strokes.

Merck agreed in November to pay $4.85 billion to settle about 27,000 Vioxx cases, with individual payouts to be determined at a later date. The Garza case was excluded from the settlement.

Garza v. Merck was the sixth overall Vioxx case to go to trial after the company voluntarily pulled the drug from the market. Juries have decided in favor of Merck 12 times and in plaintiffs' favor five times.

The Garza decision reverses one of the five plaintiffs' verdicts and results in a decision in Merck's favor. One of the previous Merck verdicts was set aside by the court and has not been retried. Another Merck verdict was set aside and retried, leading to one of the plaintiff verdicts. There have been two unresolved mistrials.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...